Dr Meir Pugatch, of the University of Haifa, argued that ACTA will not have an impact on access to generic medicine, as the agreement does not cover patents.
Meirs Pugačs no Haifas Universitātes atgādināja, ka ACTA nedz bloķē piekļuvi ģenēriskajiem medikamentiem, nedz to atvieglo.